Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991054518> ?p ?o ?g. }
- W2991054518 endingPage "371" @default.
- W2991054518 startingPage "361" @default.
- W2991054518 abstract "ALM201 is a therapeutic peptide derived from FKBPL that has previously undergone preclinical and clinical development for oncology indications and has completed a Phase 1a clinical trial in ovarian cancer patients and other advanced solid tumours.In vitro, cancer stem cell (CSC) assays in a range of HGSOC cell lines and patient samples, and in vivo tumour initiation, growth delay and limiting dilution assays, were utilised. Mechanisms were determined by using immunohistochemistry, ELISA, qRT-PCR, RNAseq and western blotting. Endogenous FKBPL protein levels were evaluated using tissue microarrays (TMA).ALM201 reduced CSCs in cell lines and primary samples by inducing differentiation. ALM201 treatment of highly vascularised Kuramochi xenografts resulted in tumour growth delay by disruption of angiogenesis and a ten-fold decrease in the CSC population. In contrast, ALM201 failed to elicit a strong antitumour response in non-vascularised OVCAR3 xenografts, due to high levels of IL-6 and vasculogenic mimicry. High endogenous tumour expression of FKBPL was associated with an increased progression-free interval, supporting the protective role of FKBPL in HGSOC.FKBPL-based therapy can (i) dually target angiogenesis and CSCs, (ii) target the CD44/STAT3 pathway in tumours and (iii) is effective in highly vascularised HGSOC tumours with low levels of IL-6." @default.
- W2991054518 created "2019-12-05" @default.
- W2991054518 creator A5008725360 @default.
- W2991054518 creator A5009626082 @default.
- W2991054518 creator A5018614325 @default.
- W2991054518 creator A5023643377 @default.
- W2991054518 creator A5024890799 @default.
- W2991054518 creator A5026949903 @default.
- W2991054518 creator A5028387712 @default.
- W2991054518 creator A5033630240 @default.
- W2991054518 creator A5043621658 @default.
- W2991054518 creator A5043843072 @default.
- W2991054518 creator A5044992973 @default.
- W2991054518 creator A5045651335 @default.
- W2991054518 creator A5047147758 @default.
- W2991054518 creator A5048735052 @default.
- W2991054518 creator A5050390957 @default.
- W2991054518 creator A5057132638 @default.
- W2991054518 creator A5060088187 @default.
- W2991054518 creator A5071021600 @default.
- W2991054518 creator A5076598668 @default.
- W2991054518 creator A5077653010 @default.
- W2991054518 creator A5079566055 @default.
- W2991054518 creator A5080850326 @default.
- W2991054518 creator A5081151755 @default.
- W2991054518 creator A5086873593 @default.
- W2991054518 creator A5089061061 @default.
- W2991054518 creator A5089145091 @default.
- W2991054518 date "2019-11-27" @default.
- W2991054518 modified "2023-10-18" @default.
- W2991054518 title "FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer" @default.
- W2991054518 cites W1480012785 @default.
- W2991054518 cites W1893019374 @default.
- W2991054518 cites W1973570584 @default.
- W2991054518 cites W1980425802 @default.
- W2991054518 cites W1982174937 @default.
- W2991054518 cites W1997338647 @default.
- W2991054518 cites W1999261571 @default.
- W2991054518 cites W2007337140 @default.
- W2991054518 cites W2019340101 @default.
- W2991054518 cites W2025418258 @default.
- W2991054518 cites W2032843265 @default.
- W2991054518 cites W2040103531 @default.
- W2991054518 cites W2044905529 @default.
- W2991054518 cites W2046434779 @default.
- W2991054518 cites W2051631209 @default.
- W2991054518 cites W2060631540 @default.
- W2991054518 cites W2072423488 @default.
- W2991054518 cites W2089542415 @default.
- W2991054518 cites W2090534211 @default.
- W2991054518 cites W2101885447 @default.
- W2991054518 cites W2103985017 @default.
- W2991054518 cites W2105624032 @default.
- W2991054518 cites W2111900617 @default.
- W2991054518 cites W2131593373 @default.
- W2991054518 cites W2135925682 @default.
- W2991054518 cites W2136658587 @default.
- W2991054518 cites W2138644182 @default.
- W2991054518 cites W2138784667 @default.
- W2991054518 cites W2149862161 @default.
- W2991054518 cites W2163041215 @default.
- W2991054518 cites W2167049762 @default.
- W2991054518 cites W2169559326 @default.
- W2991054518 cites W2170552969 @default.
- W2991054518 cites W2198386817 @default.
- W2991054518 cites W2214802907 @default.
- W2991054518 cites W2257235773 @default.
- W2991054518 cites W2278562290 @default.
- W2991054518 cites W2285354269 @default.
- W2991054518 cites W2334067795 @default.
- W2991054518 cites W2344322811 @default.
- W2991054518 cites W2620065392 @default.
- W2991054518 cites W2761220110 @default.
- W2991054518 cites W2771290640 @default.
- W2991054518 cites W2791903162 @default.
- W2991054518 cites W2793944495 @default.
- W2991054518 cites W2796576424 @default.
- W2991054518 cites W2943635746 @default.
- W2991054518 cites W4211147776 @default.
- W2991054518 doi "https://doi.org/10.1038/s41416-019-0649-5" @default.
- W2991054518 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7000737" @default.
- W2991054518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31772325" @default.
- W2991054518 hasPublicationYear "2019" @default.
- W2991054518 type Work @default.
- W2991054518 sameAs 2991054518 @default.
- W2991054518 citedByCount "36" @default.
- W2991054518 countsByYear W29910545182020 @default.
- W2991054518 countsByYear W29910545182021 @default.
- W2991054518 countsByYear W29910545182022 @default.
- W2991054518 countsByYear W29910545182023 @default.
- W2991054518 crossrefType "journal-article" @default.
- W2991054518 hasAuthorship W2991054518A5008725360 @default.
- W2991054518 hasAuthorship W2991054518A5009626082 @default.
- W2991054518 hasAuthorship W2991054518A5018614325 @default.
- W2991054518 hasAuthorship W2991054518A5023643377 @default.
- W2991054518 hasAuthorship W2991054518A5024890799 @default.
- W2991054518 hasAuthorship W2991054518A5026949903 @default.
- W2991054518 hasAuthorship W2991054518A5028387712 @default.